AdamJonathanSavitzMD

Assistant Attending Psychiatrist, NewYork-Presbyterian Hospital. Clinical Assistant Professor of Psychiatry (Courtesy), Weill Cornell Medical College, Cornell University.

Join to view full profile

Dr. Savitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Savitz's full profile

Already have an account?

Office
21 Bloomingdale Rd
White Plains, NY 10605
Phone+1 914-997-4394

Fax+1 914-682-6906

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1995 - 1998
David Geffen School of Medicine at UCLAClass of 1994

Certifications & Licensure

NY State Medical License 2001 - 2026

Clinical Trials

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia Start of enrollment: 2005 Sep 01
Completed
Phase 3

Publications & Presentations

PubMed

Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial.
Sofie Mesens, Iva Kezic, Peter Van Der Ark, Mila Etropolski, Gahan Pandina
Molecular Psychiatry. 2024-12-11
3 citations
Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective.
Amit Etkin, Jessica Powell, Adam J Savitz
Neuropsychopharmacology. 2024-11-01
2 citations
Abnormal semantic processing of threat words associated with excitement and hostility symptoms in schizophrenia.
Sara Dar, Einat Liebenthal, Hong Pan, Thomas E. Smith, Adam Savitz
Schizophrenia Research. 2021-02-01

Journal Articles

The Open Translational Science in Schizophrenia (OPTICS) Project: An Open-Science Project Bringing Together Janssen Clinical Trial and NIMH Data
Eva C Guinan, Joseph S Ross, Adam J Savitz, Nature

Press Mentions

Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of NeuropsychopharmacologyDecember 8th, 2022
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderJuly 17th, 2024